The MET-targeted anticancer therapy ‘Tepmetko’ can now be prescribed at general hospitals in Korea.

According to industry sources, ‘Tepmetko (tepotinib),’ a treatment for patients with locally advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations, passed the drug committees (DCs) of various medical institutions in Korea including Seoul National University Hospital, Konyang University Hospital, Chungnam National University Hospital, Chungbook National University Hospital, Kyungpook National University Chilgok Hospital, and Hanyang University Medical Center.

The drug has been slowly expanding its scope of prescriptions since its official release in Octob